Highest-materiality recent filing
Forian completes acquisition by 2025 Acquisition Company at $2.17/share; to delist from Nasdaq
6,444,415 shares validly tendered; together with Buyer Parties' 21,991,929 shares, ~91% of outstanding shares.
Forian to be taken private at $2.17/share in all-cash deal led by CEO Max Wygod
All-cash transaction values Forian equity at ~$68M; shareholders receive $2.17/share.
Forian Q4 revenue up 37% but net loss widens; CEO-led buyout proposal in play
Revenue Q4 $8.0M (+37% YoY); full year $30.3M (+50% YoY).
Forian Q3 revenue up 66% to $7.8M; adjusted EBITDA rises 153% to $471K
Revenue $7.76M vs $4.69M YoY; net loss improved to $151K from $205K.
Forian receives go-private proposal from CEO at $2.10/share
CEO Max Wygod leads group proposing to acquire Forian at $2.10 per share for other shareholders.
Forian Q2 revenue $7.5M (+56% YoY); net income $0.2M, EPS $0.01 vs loss
Revenue $7.48M, up 56% from $4.78M in Q2 2024; net income of $0.22M vs loss of $2.55M.
Forian Inc. dismisses CBIZ CPAs, appoints BDO USA as new auditor
On June 26, 2025, the Audit Committee dismissed CBIZ CPAs P.C. as independent registered public accounting firm.
Forian Q1 revenue $7.1M (+45% YoY), net loss narrows to $1.1M; FY25 rev guidance $28-30M
Revenue of $7.06M vs $4.88M prior year, a 45% increase driven by acquisitions and new logos.
Forian to restate 2023 and Q3 2024 financials due to revenue recognition error
Audit Committee determined 2023 quarterly/annual and Q3 2024 financials are no longer reliable.
Forian Q3 revenue down 12%, net loss of $0.2M; redeems $16M in convertible notes
Revenue of $4.69M, down 12% YoY from $5.35M; net loss of $0.2M vs prior-year income of $4.3M.
Forian Q2 revenue down 2% YoY, net loss widens to $2.6M; updates FY guidance
Revenue $4.78M vs $4.89M YoY (-2%); net loss $2.55M ($0.08 diluted loss) vs $1.12M ($0.03 loss).
Forian Q4 revenue $5.4M, net income $1.39M; FY 2024 guidance 5-15% revenue growth
Q4 2023 revenue $5.37M (+8% YoY); net income $1.39M vs loss $3.56M prior year.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
At the Effective Time, Mark J. Adler, M.D., Ian G. Banwell, Adam Dublin, Jennifer Hajj, Shahir Kassam-Adams, Alyssa Varadhan and Kristiina Vuori, M.D., Ph.D. each resigned from the board of directors of the Company (the “ Board ”) and from all committees of the Board on which they served, and Max Wygod remained as the sole director of the Surviving Corporation.
On April 28, 2025, Edward Spaniel, Jr., Executive Vice President, General Counsel and Corporate Secretary of Forian Inc. (the “Company”), notified the Company of his resignation from all of his positions with the Company and its subsidiaries and affiliates, effective May 23, 2025.
Max materiality 1.00 · Median 0.65 · Most common event earnings